Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy
-
Published:2021-12
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Kamel S. M.ORCID, van Opbergen C. J. M.ORCID, Koopman C. D., Verkerk A. O.ORCID, Boukens B. J. D., de Jonge B., Onderwater Y. L.ORCID, van Alebeek E., Chocron S., Polidoro Pontalti C., Weuring W. J.ORCID, Vos M. A., de Boer T. P.ORCID, van Veen T. A. B.ORCID, Bakkers J.ORCID
Abstract
AbstractThe heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca2+ dynamics. Little is known about the physiological processes preceding induced cardiomyopathy, which is characterized by sub-epicardial accumulation of fibrofatty tissue, and a specific drug treatment is currently lacking. Here, we address these issues using a knock-in Phospholamban p.Arg14del zebrafish model. Hearts from adult zebrafish with this mutation display age-related remodeling with sub-epicardial inflammation and fibrosis. Echocardiography reveals contractile variations before overt structural changes occur, which correlates at the cellular level with action potential duration alternans. These functional alterations are preceded by diminished Ca2+ transient amplitudes in embryonic hearts as well as an increase in diastolic Ca2+ level, slower Ca2+ transient decay and longer Ca2+ transients in cells of adult hearts. We find that istaroxime treatment ameliorates the in vivo Ca2+ dysregulation, rescues the cellular action potential duration alternans, while it improves cardiac relaxation. Thus, we present insight into the pathophysiology of Phospholamban p.Arg14del cardiomyopathy.
Funder
Hartstichting ZonMw
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference65 articles.
1. Corrado, D., Basso, C. & Judge, D. P. Arrhythmogenic cardiomyopathy. Circ. Res. 121, 784–802 (2017). 2. Podgoršek, B., Poglajen, G., Cerar, A., Šinkovec, M. & Vrtovec, B. Arrhythmogenic cardiomyopathy. Zdr. Vestn. 87, 599–617 (2019). 3. Sommariva, E., Stadiotti, I., Perrucci, G. L., Tondo, C. & Pompilio, G. Cell models of arrhythmogenic cardiomyopathy: advances and opportunities. DMM Dis. Models Mech. 10, 823–835 (2017). 4. Hof, I. E. et al. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth. Hear. J. 27, 64–69 (2019). 5. DeWitt, M. M., MacLeod, H. M., Soliven, B. & McNally, E. M. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1396–1398 (2006).
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|